Therapeutic drug monitoring · 2026
Biogeneric Native and Polyethylene Glycol-conjugated Escherichia coli Asparaginases for Treating Children with Acute Lymphoblastic Leukemia.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Datta Neerajana, Jana Bishwaranjan, Goswami Srijani, Roy Annwesha, Samaddar Samik, Kundu Subhajit, Gogoi Manash P, Dasgupta Bony, Dutta Trina, Das Nandana, Saha Vaskar, Sidhu Jasmeet, Krishnan Shekhar
Аннотация
BACKGROUND: Escherichia coli asparaginases (EcASNase) available for the treatment of children with acute lymphoblastic leukemia are largely of suboptimal quality in low-middle income countries and contribute to inferior outcomes.
METHODS: The pharmacokinetics, activity, and immunogenicity of a native (EcASNase) and a PEGylated ASNase (PEG-EcASNase) were analyzed. Biogeneric EcASNase (10,000 IU/m2) was administered intramuscularly every 72 hours (cohort 1, 76 patients) or every 48 hours (cohort 2, 69 patients). Cohort 3 (176 patients) received a PEG-EcASNase biogeneric (1000 IU/m2) intramuscularly every 14 days.
RESULTS: In cohort 1, 69% of trough induction samples were suboptimal (<100 IU/L). Cohort 2 achieved a median trough activity >600 IU/L during induction, with no suboptimal activity. The median trough activity during induction in cohort 3 was 467 IU/L, with suboptimal activity observed in 7%-16%. Patients receiving 1 induction PEG-EcASNase dose had 8-fold higher odds of suboptimal activity postinduction. Hypersensitivity was higher with EcASNase (12% versus 5%) and pancreatitis, more often with PEG-EcASNAse (5% versus 1%). Antidrug antibodies were strongly associated with silent inactivation and hypersensitivity (P < 0.0001).
CONCLUSIONS: Pharmacological monitoring enabled optimization of EcASNase dosing, detection of silent PEG-EcASNase inactivation, and identification of induction dosing intensity as a determinant of sustained activity for generic ASNase products marketed in low-middle income countries.
METHODS: The pharmacokinetics, activity, and immunogenicity of a native (EcASNase) and a PEGylated ASNase (PEG-EcASNase) were analyzed. Biogeneric EcASNase (10,000 IU/m2) was administered intramuscularly every 72 hours (cohort 1, 76 patients) or every 48 hours (cohort 2, 69 patients). Cohort 3 (176 patients) received a PEG-EcASNase biogeneric (1000 IU/m2) intramuscularly every 14 days.
RESULTS: In cohort 1, 69% of trough induction samples were suboptimal (<100 IU/L). Cohort 2 achieved a median trough activity >600 IU/L during induction, with no suboptimal activity. The median trough activity during induction in cohort 3 was 467 IU/L, with suboptimal activity observed in 7%-16%. Patients receiving 1 induction PEG-EcASNase dose had 8-fold higher odds of suboptimal activity postinduction. Hypersensitivity was higher with EcASNase (12% versus 5%) and pancreatitis, more often with PEG-EcASNAse (5% versus 1%). Antidrug antibodies were strongly associated with silent inactivation and hypersensitivity (P < 0.0001).
CONCLUSIONS: Pharmacological monitoring enabled optimization of EcASNase dosing, detection of silent PEG-EcASNase inactivation, and identification of induction dosing intensity as a determinant of sustained activity for generic ASNase products marketed in low-middle income countries.